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Abstract: Muscarinic and nicotinic cholinergic receptors 
and choline acetyltransferase activity were studied in post- 
mortem brain tissue from patients with histopathologically 
confirmed Parkinson’s disease and matched control sub- 
jects. Using washed membrane homogenates from the fron- 
tal cortex, hippocampus, caudate nucleus, and putamen, 
saturation analysis of specific receptor binding was per- 
formed for the total number of muscarinic receptors with 
[3H]quinuclidinyl benzilate, for muscarinic M, receptors 
with [3H]pirenzepine, for muscarinic M2 receptors with [3H]- 
oxotremonne-M, and for nicotinic receptors with (-)-[3H]- 
nicotine. In comparison with control tissues, choline acetyl- 
transferase activity was reduced in the frontal cortex and 
hippocampus and unchanged in the caudate nucleus and 
putamen of parkinsonian patients. In Parkinson’s disease 
the maximal binding site density for [3H]quinuclidinyl ben- 
zilate was increased in the frontal cortex and unaltered in 
the hippocampus, caudate nucleus, and putamen. Specific 
[3H]pirenzepine binding was increased in the frontal cortex, 
unaltered in the hippocampus, and decreased in the caudate 
nucleus and putamen. In parkinsonian patients B,,, values 
for specific [3H]oxotremorine-M binding were reduced in 
the cortex and unchanged in the hippocampus and striatum 
compared with controls. Maximal (-)-[3H]nicotine binding 
was reduced in both the cortex and hippocampus and unal- 
tered in both the caudate nucleus and putamen. Alterations 
of the equilibrium dissociation constant were not observed 
for any ligand in any of the brain areas examined. The pres- 
ent results suggest that both the innominatocortical and the 
septohippocampal cholinergic systems degenerate in Par- 
kinson’s disease. The reduction of cortical [3H]- 
oxotremorine-M and (-)-[3H]nicotine binding is compati- 
ble with the concept that significant numbers of the binding 
sites labelled by these ligands are located on presynaptic 
cholinergic nerve terminals, whereas the increased [3H]- 
pirenzepine binding in the cortex may reflect postsynaptic 
denervation supersensitivity. Key Words: Acetylcholine- 
Choline acetyltransferase-Muscarinic receptors-Nico- 
tinic receptors-Parkinson’s disease. Lange K. W. et al. Al- 
tered muscarinic and nicotinic receptor densities in cortical 
and subcortical brain regions in Parkinson’s disease. J. 
Neurochem. 60, 197-203 (1993). 
Present evidence suggests that a central cholinergic 
deficiency is the basis of some aspects of cognitive 
dysfunction (Bartus et al., 1982). In rats and nonhu- 
man primates, a subcorticocortical cholinergic defi- 
ciency is associated with profound cognitive alter- 
ations (Ridley et al., 1985; Everitt et al., 1987). In 
Alzheimer’s disease the cortical cholinergic defi- 
ciency, as measured by choline acetyltransferase 
(ChAT) activity, has been related to intellectual im- 
pairment (Perry et al., 1978). Dementia occurs in a 
significant number of patients with Parkinson’s dis- 
ease but without substantial pathological changes typi- 
cal of Alzheimer’s disease (Candy et al., 1983; Perry et 
al., 1985). The innominatocortical and septohippo- 
campal cholinergic systems appear to be damaged in 
Parkinson’s disease, because severe neuronal loss oc- 
curs in the substantia innominata (Candy et al., 1983; 
Whitehouse et al., 1983) and ChAT activity is de- 
creased in the neocortex and hippocampus (Ruberg et 
al., 1982; Dubois et al., 1983). The loss of cortical 
ChAT activity in parkinsonian subjects has been re- 
ported to correlate with the severity of dementia (Ru- 
berg et al., 1982; Perry et al., 1985). 
The status of muscarinic and nicotinic cholinergic 
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receptor subtypes in Parkinson’s disease is less clear. 
Total muscarinic binding, identified by [3H]- 
quinuclidin yl benzilate ([ 3H]QNB), has been reported 
to be increased in the neocortex and unchanged in the 
striatum of patients with Parkinson’s disease in com- 
parison with control subjects (Reisine et al., 1977; 
Ruberg et al., 1982; Dubois et al., 1983). The increase 
of muscarinic receptor binding in the cortex may be 
due to a denervation-induced increase of postsynaptic 
muscarinic receptors (Dubois et al., 1983). Selective 
muscarinic ligands might be used to differentiate be- 
tween receptor subtypes located at pre- and postsyn- 
aptic sites. The muscarinic antagonist pirenzepine 
binds preferentially to M, muscarinic receptors, 
which are thought to be located postsynaptically, 
rather than to M, receptors, whereas QNB binds with 
the same affinity to both receptor subtypes (Hammer 
et al., 1980; Watson et al., 1983). Muscannic recep- 
tors of the M2 subtype can be selectively labelled by 
[3H]oxotremorine-M (Bevan, 1984; Spencer et al., 
1986). In addition, little attention has been paid to 
changes in nicotinic cholinergic receptors. t3H]- 
Nicotine has been described as a ligand for the charac- 
terization of nicotinic binding sites in the rat brain 
(Romano and Goldstein, I980), and (-)-[3H]nicotine 
has been shown to be highly specific for nicotinic re- 
ceptors in the human brain (Shimohama et al., 1985). 
To further elucidate the alterations of cholinergic 
systems in Parkinson’s disease and their relation to 
dementia, we have examined ChAT activity as an in- 
dex of cholinergic innervation and receptor binding 
of [3H]QNB, [3H]pirenzepine, [3H]oxotremonne-M, 
and ( -)-[3H]nicotine in cortical and subcortical brain 
regions of demented and nondemented patients with 
Parkinson’s disease. 
MATERIALS AND METHODS 
Materials 
l-Quinuclidinyl [phenyl-4-3H]benzilate ([3H]QNB; spe- 
cific activity, 39 Ci/mmol) and (-)-[N-methyl-3H]nicotine 
(specific activity, 63.5 Ci/mmol) were purchased from 
Amersham International (Amersham, Buckinghamshire, 
U.K.). [N-methyl-3H]Pirenzepine (specific activity, 70.1 Ci/ 
mmol), [rnethyl-3H]oxotremorine-M acetate (specific activ- 
ity, 84.9 Ci/mmol), and [‘4C]acetyl-CoA (specific activity, 
53 mCi/mmol) were from New England Nuclear (DuPont, 
Stevenage, Hertfordshire, U.K.). The protein assay was ob- 
tained from Bio-Rad Laboratories (Heme1 Hempstead, 
Hertfordshire, U.K.). Atropine sulfate and polyethyleni- 
mine were purchased from Sigma (Poole, Dorset, U.K.). 
The liquid scintillation cocktail (Scintillator 299 TM) was 
from Packard (Pangbourne, Berkshire, U.K.). All other re- 
agents were of analytical grade and were obtained commer- 
cially. 
Brain tissue 
Tissue samples from the frontal cortex (Brodmann area 
9), hippocampus, caudate nucleus, and putamen were ob- 
tained from 10 patients who died with the clinical diagnosis 
of idiopathic Parkinson’s disease and from 10 age-matched 
control subjects with no evidence of neurological or psychi- 
atric diseases (for patient details, see Table 1). Five parkin- 
sonian patients had shown profound progressive distur- 
bances in memory and cognitive impairment and had been 
clinically demented according to DSM 111 criteria (Ameri- 
can Psychiatric Association, 1980). The parkinsonian pa- 
tients had all received levodopa therapy up to the time of 
death and had not received anticholinergic medication. Par- 
kinson’s disease was confirmed neuropathologically by the 
presence of neuronal loss and Lewy bodies in the substantia 
nigra. The patients did not show neocortical neurofibrillary 
tangles or abundant neuritic plaques. Control subjects had 
not received any drugs known to affect the CNS. Pathologi- 
cal examination ofthe control brains revealed no abnormali- 
ties; in particular, there was no cell loss in the substantia 
nigra, and Lewy bodies were absent. According to the clini- 
cal notes, the subjects examined in this study had not been 
smokers for the last 2 years before their deaths. There was 
no difference between the Parkinson’s disease and control 
groups with regard to the time from death to body refrigera- 
tion, the time from death to brain removal, or the time of 
storage of the frozen brain samples before neurochemical 
analysis. 
At autopsy the brains were removed and divided midsagi- 
tally. One half brain was immediately frozen at -20°C and 
transported on Cardice to the Brain Bank, where the tissue 
was frozen at -70°C until dissection for neurochemical 
analyses took place. The other half brain was placed in 10% 
formol saline and was examined neuropathologically. Tis- 
sue samples were frozen for up to 2.5 years before biochemi- 
cal analysis. Immediately before dissection for ChAT activ- 
ity determination and receptor binding assays, frozen brain 
tissue was gradually raised in temperature to -12°C. The 
brainstem was then cut off between the upper margin of the 
pons and the lower border ofthe inferior colliculus to form a 
hindbrain block. A midbrain block was formed by cutting 
vertically from the posterior margin of the optic chiasm to 
the lower border of the corpus callosum. From this point, 
the brain was cut along the curved lower border of the cor- 
pus callosum to terminate at the superior margin of the 
superior colliculus. This block was removed by cutting in 
the sagittal plane along the lateral margins of the cerebral 
peduncle and tectum. The hemisphere was then sectioned 
coronally into 10 slices at - 1.2-cm intervals from the fron- 
tal lobe tips to the level of the splenium of the corpus callo- 
sum. Nuclear areas in the midbrain and coronal hemisphere 
sections were outlined by their anatomical colour/density 
features in contrast to adjacent structures identified by refer- 
ence to standard manuals of neuroanatomy. Cerebral corti- 
cal areas were located according to Brodmann’s scheme of 
localization. The brain tissue was removed in small frag- 
ments or narrow strips and stored in labelled tubes at 
-70°C until biochemical analysis. 
Biochemical analysis 
Using washed membrane homogenates from the frontal 
cortex (Brodmann area 9), hippocampus, caudate nucleus, 
and putamen, saturation analysis of specific receptor bind- 
ing was performed for the total number of muscarinic re- 
ceptors with [3H]QNB as ligand, for muscarinic M, recep- 
tors with [3H]pirenzepine, for muscarinic M, receptors with 
[3H]oxotremorine-M, and for nicotinic receptors with (-)- 
[3H]nicotine. The maximal receptor number (Bmax) and the 
equilibrium dissociation constant (KD)  were determined by 
assaying the binding of the tritiated ligands at different con- 
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TABLE 1. Patient characteristics and details ojpostmortem procedures 
Parkinson's disease 




Age at onset of Parkinson's disease (years) 
Duration of Parkinson's 
L-DOPA dosage at time of death (mgiday) 
Cell loss and presence of Lewy bodies in midbrain 
Caudate dopamine concentration (ng/g) 
Time between death and 
body refrigeration (h) 
Time between death and autopsy (h) 
disease (years) 







2,836 f 396 
2.1 2 0.4 
19.6 _+ 2.4 
69.2 f 3.3 
2 
3 
56.2 k 3.4 
13.0 +- 4.1 
303 k 88 
Yes 
324 * 133" 
2.8 i- 0.2 
18.3 f 4.1 
~ ~~ 
With dementia 
78.2 f 2.6 
3 
2 
63.6 f 1.8 
14.6 f 2.9 
525 2 77 
Yes 
297 k 152" 
2.7 rt 0.7 
17.9 & 4.0 
Data are mean ? SEM values. Caudate dopamine levels were measured by a standard HPLC with electrochemical detection technique 
(Weller et al., 1987). L-DOPA, ~-3,4-dihydroxyphenylalanine. 
" p  < 0.05 compared with control values by Student's t test. 
centrations of ['HIQNB (range, 10-300 pM), [3H]- 
pirenzepine (0.5-64 nM), [3H]oxotremorine-M (0.25-32 
nM), and (-)-[3H]nicotine (0.5-64 nM). Binding data were 
expressed as femtomoles of tritiated ligand specifically 
bound per milligram of protein. 
For [3H]QNB binding, tissue homogenates of each brain 
region examined were initially prepared in ice-cold 0.05 M 
sodium/potassium phosphate buffer (pH 7.4) by hand over 
a 30-s period using 3 complete strokes of a Teflon-glass 
homogenizer. The homogenates were centrifuged (48,000 g 
for 10 min at 4°C). The resulting pellet was homogenized 
using a 10-s burst with a Polytron homogenizer (setting of 7; 
Kinematica, Luzern, Switzerland) at 4°C and then washed 
twice in fresh buffer and recentrifuged as above. The homog- 
enate was finally resuspended in the sodium/potassium 
phosphate buffer. [3H]QNB binding was camed out on tis- 
sue corresponding to 15-50 pg of protein in a total volume 
of 7.0 ml, at 37°C for 60 min. Nonspecific binding was 
determined by carrying out incubations in the presence of 
unlabelled atropine (1 pM).  After incubation for 60 min, 
the reaction was stopped by addition of ice-cold assay buffer 
and rapid filtration under reduced pressure through glass 
fiber filters (Whatman GF/C), presoaked in assay buffer, 
with a Brandel cell harvester (Semat, St. Albans, Hertford- 
shire, U.K.). The filters were rinsed with three 5-ml aliquots 
of buffer and dried for - 12 h. They were then placed into 
scintillation vials, and 5 ml of scintillation fluid was added 
to extract tissue-bound radioactivity for - 12 h at ambient 
temperature. Samples were cooled for 2-3 h before quantifi- 
cation by liquid scintillation spectrophotometry (model 
Tri-Carb 460C; Packard) at a counting efficiency of 45%. 
For [3H]pirenzepine binding, brain tissue homogenates 
were prepared as described for [3H]QNB binding. The spe- 
cific binding of [3H]pirenzepine was measured in parallel 
assays, which were conducted in the designated assay buffer 
as described above in a total volume of 0.1 ml, at 37°C for 
60 min, again using 1 p M  atropine to define nonspecific 
binding. It was necessary to presoak GF/C filters in aqueous 
polyethylenimine (0.1%) for 30 min to reduce filter binding 
of the polar [3H]pirenzepine (Watson et al., 1983). 
For [3H]oxotremorine-M and (-)-[3H]nicotine binding, 
brain tissue was suspended and homogenized in an ice-cold 
buffer (pH 7.4) containing 118 mMNaCl,4.8 mMKCl,2.5 
m M  CaCl,, 1.2 mM MgCl,, and 20 m M  HEPES. The ho- 
mogenates were washed twice by centrifugation at 48,000 g 
for 10 min with intermediate homogenization with a Poly- 
tron (setting of 7, 10 s, 4°C) in fresh buffer. 
For [3H]oxotremorine-M and (-)-['H]nicotine binding, 
polypropylene tubes containing the ligand and tissue mem- 
branes (240-360 pg of protein) to a final volume of 250 p1 
were incubated at 25°C for 10 min. Nonspecific binding 
was defined as binding in the presence of 1 pM atropine or 
10 pM(-)-nicotine, respectively. The binding assay was ter- 
minated by addition of 4 ml of ice-cold wash buffer (compo- 
sition identical with that of incubation buffer, except that 
the HEPES concentration was reduced to 5 mM) and then 
filtration under reduced pressure through Whatman GF/C 
glass fiber filters, previously soaked in a 0.1 % solution of 
polyethylenimine. The filters were subsequently washed 
twice with 4 ml of wash buffer. 
All binding assays were carried out in triplicate, the values 
of which did not vary by >8%. Homogenates were added 
promptly to begin binding assays immediately after they 
were prepared. Total binding was limited to ensure that 
there would be no significant depletion of free ligand during 
the binding assay and that specific binding was always 
S O %  of total binding. All measurements of cholinergic 
binding sites and ChAT activity were made blind with re- 
spect to diagnosis. 
Aliquots for the determination of the activity of ChAT 
(acetyl-CoA:choline 0-acetyltransferase; EC 2.3.1.6) were 
removed from the tissue homogenates of each brain area 
examined. ChAT activity was determined by a radioenzy- 
matic method measuring the formation of ['CC]- 
acetylcholine from ['4C]acetyl-CoA and choline (Fonnum, 
1975). Tissue samples were homogenized in 10 mMEDTA 
(pH 7.4). ChAT activity was expressed in nanomoles of ace- 
tylcholine formed per hour per milligram of protein. 
The protein concentration was measured with the Bio- 
Rad protein assay (Bradford, 1976) in aliquots of the mem- 
brane suspensions used in the receptor binding assays. 
Data analysis 
The B,, and the K,, were determined by Eadie-Hofstee 
analysis. Results are expressed as mean k SEM values. De- 
mented and nondemented parkinsonian patients were com- 
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pared with control subjects by the nonparametnc Wil- 
coxon's rank-sum test (Wilcoxon, 1945). 
RESULTS 
ChAT activity 
ChAT activity was reduced in both frontal cortex 
and hippocampus of demented and nondemented pa- 
tients with Parkinson's disease compared with control 
tissues (Fig. 1). In demented parkinsonian patients 
ChAT activity in the cortex and hippocampus was 
decreased to a greater extent than in nondemented 
patients. ChAT activity was unchanged in the caudate 
nucleus and putamen of parkinsonian subjects com- 
pared with controls. 
Muscarinic receptor binding 
In demented and nondemented parkinsonian sub- 
jects, the &,, for the total number of muscarinic re- 
ceptors as measured by specific binding of [3H]QNB 
was increased in the frontal cortex and unaltered in 
the hippocampus, caudate nucleus, and putamen 
(Fig. 2). Specific binding of [3H]pirenzepine was in- 
creased in the frontal cortex, unaltered in the hippo- 
campus, and decreased in the caudate nucleus and 
putamen (Fig. 2). In Parkinson's disease B,,, values 
for specific [ 3H]oxotremorine-M binding were re- 
duced in the cortex and unchanged in the hippocam- 
pus and stnatum compared with controls (Fig. 2). The 
KD values for [3H]QNB, [3H]pirenzepine, and [3H]- 
oxotremorine-M did not differ between the groups of 
patients and control subjects in the brain areas exam- 
ined. 
Nicotinic receptor binding 
Compared with the control group, the density of 
nicotinic receptors as identified by specific (-)-[3H]- 
nicotine bindling was reduced in both the frontal cor- 
tex and hippocampus and unchanged in the caudate 
nucleus and putamen (Fig. 3) .  Alterations of KD val- 
ues for (-)-[3H]nicotine binding were not seen. 
DISCUSSION 
ChAT activil-y 
The reduction of ChAT activity in the neocortex 
and hippocampus was more pronounced in de- 
mented than in nondemented parkinsonian subjects. 
This confirms the findings of previous reports (Ru- 
FIG. 1. ChAT activity, measured by the 
formation of ['4C]acetylcholine from 
['4C]acetyl-CoA and choline, in different 
brain areas from 10 control subjects (0) 
and five nondemented (B) and five de- 
mented (m) patients with Parkinson's 
disease. Data are mean i SEM (bars) 
values. ' p  < 0.05 compared with con- 
trol values, ' p  < 0.05 compared with 
nondemented patients with Parkin- 
son's disease by Wilcoxon's rank-sum 
P u t a m e n  test. 
berg et al., 1982; Dubois et al., 1983; Smith et al., 
1988). It has been shown that the decrease in cortical 
ChAT activity is correlated with the cell loss in the 
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FIG. 2. Specific binding of (A) [3H]ONB, (B) r3H]pirenzepine, and 
(C) [3H]oxotremorine-M to muscarinic sites in different brain areas 
from 10 control subjects (0) and five nondemented (I@ and five 
demented (M) patients with Parkinson's disease. Saturation analy- 
ses were performed in tissue homogenates incubated with 10- 
300 pM [3H]QNB, 0.5-64 nM [3H]pirenzepine, and 0.25-32 nM 
[3H]oxotremorine-M, respectively. Data are mean t SEM (bars) 
values. *p < 0.05 compared with control values by Wilcoxon's 
rank-sum test. 
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FIG. 3. Specific binding of (-)-[3H]nicotine to nicotinic sites in 
different brain areas from 10 control subjects (0) and five nonde- 
mented (B) and five demented (m) patients with Parkinson’s dis- 
ease. Saturation analyses were performed in tissue homoge- 
nates incubated with 0.5-64 nM (-)-[3H]nicotine. Data are mean 
f SEM (bars) values. *p < 0.05 compared with control values by 
Wilcoxon’s rank-sum test. 
son’s disease (Perry et al., 1985). Even parkinsonian 
subjects without cognitive impairment showed mark- 
edly decreased cortical ChAT activity in this and pre- 
vious studies (Ruberg et al., 1982; Dubois et al., 1983) 
and neuronal loss in the substantia innominata (Na- 
kano and Hirano, 1984), indicating the beginning of 
degeneration in the innominatocortical cholinergic 
system. A subthreshold dose of scopolamine does not 
induce a deterioration in performance of control sub- 
jects in a memory test battery but does reduce perfor- 
mance of parkinsonian patients without cognitive im- 
pairment (Dubois et al., 1987). These findings suggest 
that nondemented parkinsonian subjects have an al- 
teration of central cholinergic transmission that is in- 
volved in memory-related cognitive function. 
ChAT activity in the caudate nucleus and putamen 
was unchanged in this and previous studies (Ruberg et 
al., 1982; Sirvio et al., 1989), indicating intact striatal 
cholinergic innervation. This corresponds with neuro- 
pathological findings that the striatum is generally 
free of lesions in Parkinson’s disease (Jellinger, 1987). 
The striatum is rich in cholinergic structures, and le- 
sions of striatal afferents and efferents fail to induce a 
major loss of ChAT and acetylcholinesterase, indicat- 
ing that the majority of ChAT is contained in inter- 
neurones (Butcher and Butcher, 1974; McGeer et al., 
197 1). 
Muscarinic receptor binding 
The B,,, values for specific [3H]QNB binding in 
the control subjects are well in accord with those re- 
ported by others (Ruberg et al., 1982). Thus, [3H]- 
QNB binding was high in the putamen and caudate 
nucleus, intermediate in the frontal cortex, and low in 
the hippocampus. A similar distribution was observed 
for the B,, values for specific [3H]pirenzepine bind- 
ing. These results agree with the findings of previous 
studies (Cortts et al., 1986; Quirion et al., 1989). 
Increased concentrations of the total number of 
muscarinic cholinergic receptors in Parkinson’s dis- 
ease have been described in previous reports (Ruberg 
et al., 1982; Sirvio et al., 1989). However, at least 
some of the patients examined in these studies had 
received anticholinergic drugs before death, and the 
increase in receptor numbers was possibly induced by 
the medication (Westlind et al., 198 1). In the present 
study the parkinsonian patients had not received anti- 
cholinergics. The increase in number of muscarinic 
receptors and in particular of M, receptors, which are 
thought to be located mainly postsynaptically (Mash 
et al., 1985), may therefore reflect denervation super- 
sensitivity due to reduced presynaptic cholinergic ac- 
tivity. Altered cholinergic transmission may not, in its 
early stages, be entirely expressed functionally, be- 
cause increased concentrations ofpostsynaptic musca- 
rink receptors can compensate for the cholinergic def- 
icit and maintain normal cognitive function. 
In the cortex the concentration of putative M, mus- 
carinic receptors identified by specific [3H]oxotrem- 
orine-M binding is markedly decreased. A similar re- 
duction of [3H]oxotremorine-M binding has been 
shown in Alzheimer’s disease (Mash et al., 1985), and 
these results appear to support the hypothesis that M, 
receptors are located on presynaptic cholinergic nerve 
terminals and are partly lost due to degeneration of 
the ascending innominatocortical pathway. This view 
is supported by the observation that cortical [3H]- 
oxotremorine-M binding is decreased to the same de- 
gree as ChAT activity following bilateral nucleus ba- 
salis lesions in the rat (K. W. Lange, unpublished 
data). 
The increase in the number of M, receptors and the 
reduction in number of M, receptors in the cortex in 
Parkinson’s disease have pharmacological implica- 
tions. As the cholinergic nerve terminals seem to de- 
generate in patients with Parkinson’s disease, a possi- 
ble replacement therapy of the cholinergic deficit has 
to concentrate on postsynaptic M, receptors. It ap- 
pears therefore to be necessary to avoid M, antago- 
nists, which are commonly used to treat the motor 
disorders of parkinsonian patients. Cholinergic re- 
placement as a treatment of the cognitive dysfunction 
in Parkinson’s disease should be beneficial because 
most of the cortical target cells seem to be intact. 
There is, however, a risk of aggravating the motor 
symptoms by cholinergic agonists (Duvoisin, 1967). 
The result of unchanged [3H]QNB binding in the 
caudate nucleus confirms the findings of other studies 
(Reisine et al., 1977; Ruberg et al., 1982; Sirvio et al., 
1989). A decrease in number of muscarinic MI recep- 
tors measured by specific [3H]pirenzepine binding 
was previously shown in another study (Sirvio et al., 
1989). The connections between cholinergic inter- 
neurones and pathways to and from the striatum are 
not well understood. Animal studies suggest that the 
nigrostriatal dopaminergic neurones have synaptic 
contact with ChAT-containing dendritic processes 
(Hattori et al., 1976) and inhibit the activity of the 
cholinergic neurones (Connor, 1970). Some musca- 
rinic receptors may be located on dopaminergic nerve 
terminals in the caudate nucleus (Fibiger, 1982; Gray- 
J. Neurochem., Val. 60, No. I ,  1993 
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biel et al., 1986). As dopaminergic neurones project- 
ing from the siibstantia nigra to the striatum degener- 
ate in Parkinson’s disease (Jellinger, 1987), the de- 
crease in the number of [3H]pirenzepine binding sites 
in the striatuni could be explained by a possible loca- 
tion of M, receptors on nigrostriatal dopaminergic 
axon terminals. This view is underlined by the finding 
that after heniitransection of the nigrostriatal path- 
way in the rat, a substantial reduction of [3H]- 
pirenzepine receptors is observed in the striatum ipsi- 
lateral to the lesion (Pittaluga et al., 1987). 
It is interesting to note that the concentrations of 
M2 binding sites in the cortex, hippocampus, and cau- 
date nucleus of control and parkinsonian subjects are 
similar when determined by specific [3H]oxotrem- 
orine-M binding or by the subtractive method using 
the difference between [3H]QNB binding and [3H]- 
pirenzepine binding as an estimate for M, site density 
(Fig. 2). These values are, however, quite different in 
the putamen. There was no alteration in the concen- 
tration of M, sites when determined by [3H]oxotrem- 
orine-M binding, but there appears to be an increase 
when determined by the subtractive method (Fig. 2). 
Nicotinic receptor binding 
In control subjects the putamen showed the highest 
level of specific ( -)-[3H]nicotine binding, with lower 
binding being seen in the frontal cortex, hippocam- 
pus, and caudate nucleus. This distribution was in 
good agreement with data reported previously (Shi- 
mohama et al., 1986). 
As the subjects examined had not been smokers in 
the 2 years before death, an increase in the density of 
( -)-[3H]nicotine binding sites as a result of tobacco 
smoking can probably be excluded (Benwell et al., 
1988). The present results suggest that the concentra- 
tions of cortical and hippocampal nicotinic receptors 
are reduced in Parkinson’s disease. Reduced nicotinic 
receptor bincling was previously reported in the hip- 
pocampus (Perry et al., 1987) and cortex (Whitehouse 
et al., 1988a,b). The exact cellular location of nico- 
tinic receptors in the cortex and hippocampus is not 
known. The parallel changes in these receptors and 
ChAT activity suggest that the receptor is at least 
partly associated with cholinergic innervation and pre- 
sumably located presynaptically on degenerating cho- 
linergic axons. The nucleus basalis of Meynert, which 
is the principlal nucleus of the basal forebrain cholin- 
ergic system and innervates the cortex, has the highest 
concentrations of nicotinic receptors in the human 
brain (Shimohama et al., 1986). The degeneration of 
nucleus basalis neurones in Parkinson’s disease may 
result in reductions in content of cortical presynaptic 
markers, including nicotinic receptors. Consistent 
with the idea of presynaptic location of nicotinic bind- 
ing sites is the finding that nicotine stimulates the re- 
lease of acetylcholine from cholinergic terminals in 
the cortex (B,alfour, 1982; Rowel1 and Winkler, 1984). 
Nicotine affects performance in various attentional 
tasks, including those requiring vigilance and divided 
attention (Wesnes and Warburton, 1983). In animals 
and humans nicotinic agonists have been shown to 
improve performance on learning tasks (Flood et al., 
1981; Wesnes and Warburton, 1984). The present 
findings of reduced numbers of cortical nicotinic re- 
ceptors point to the potential for stimulation of the 
remaining nicotinic receptors with nicotinic agonists 
as a treatment of the cholinergic deficit associated 
with cognitive impairment in Parkinson’s disease. 
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